Search details
1.
Deubiquitinase USP9X loss sensitizes renal cancer cells to mTOR inhibition.
Int J Cancer
; 153(6): 1300-1312, 2023 09 15.
Article
in English
| MEDLINE | ID: mdl-37260183
2.
Recurrent Germline DLST Mutations in Individuals with Multiple Pheochromocytomas and Paragangliomas.
Am J Hum Genet
; 104(4): 651-664, 2019 04 04.
Article
in English
| MEDLINE | ID: mdl-30929736
3.
Prevalence of pathogenic germline variants in patients with metastatic renal cell carcinoma.
Genet Med
; 23(4): 698-704, 2021 04.
Article
in English
| MEDLINE | ID: mdl-33442023
4.
PTEN expression and mutations in TSC1, TSC2 and MTOR are associated with response to rapalogs in patients with renal cell carcinoma.
Int J Cancer
; 146(5): 1435-1444, 2020 03 01.
Article
in English
| MEDLINE | ID: mdl-31335987
5.
Hsa-miR-139-5p is a prognostic thyroid cancer marker involved in HNRNPF-mediated alternative splicing.
Int J Cancer
; 146(2): 521-530, 2020 01 15.
Article
in English
| MEDLINE | ID: mdl-31403184
6.
Molecular characterization of chromophobe renal cell carcinoma reveals mTOR pathway alterations in patients with poor outcome.
Mod Pathol
; 33(12): 2580-2590, 2020 12.
Article
in English
| MEDLINE | ID: mdl-32616874
7.
Transposon mutagenesis identifies chromatin modifiers cooperating with Ras in thyroid tumorigenesis and detects ATXN7 as a cancer gene.
Proc Natl Acad Sci U S A
; 114(25): E4951-E4960, 2017 06 20.
Article
in English
| MEDLINE | ID: mdl-28584132
8.
Concomitant Medications and Risk of Chemotherapy-Induced Peripheral Neuropathy.
Oncologist
; 24(8): e784-e792, 2019 08.
Article
in English
| MEDLINE | ID: mdl-30470691
9.
Gain-of-function mutations in DNMT3A in patients with paraganglioma.
Genet Med
; 20(12): 1644-1651, 2018 12.
Article
in English
| MEDLINE | ID: mdl-29740169
10.
Biallelic TSC2 Mutations in a Patient With Chromophobe Renal Cell Carcinoma Showing Extraordinary Response to Temsirolimus.
J Natl Compr Canc Netw
; 16(4): 352-358, 2018 04.
Article
in English
| MEDLINE | ID: mdl-29632054
11.
Recurrent Germline DLST Mutations in Individuals with Multiple Pheochromocytomas and Paragangliomas.
Am J Hum Genet
; 104(5): 1008-1010, 2019 May 02.
Article
in English
| MEDLINE | ID: mdl-31051110
12.
Exceptional Response to Temsirolimus in a Metastatic Clear Cell Renal Cell Carcinoma With an Early Novel MTOR-Activating Mutation.
J Natl Compr Canc Netw
; 15(11): 1310-1315, 2017 11.
Article
in English
| MEDLINE | ID: mdl-29118224
13.
Recommendations for somatic and germline genetic testing of single pheochromocytoma and paraganglioma based on findings from a series of 329 patients.
J Med Genet
; 52(10): 647-56, 2015 Oct.
Article
in English
| MEDLINE | ID: mdl-26269449
14.
Genomic and immune landscape Of metastatic pheochromocytoma and paraganglioma.
Nat Commun
; 14(1): 1122, 2023 02 28.
Article
in English
| MEDLINE | ID: mdl-36854674
15.
Genome-wide analysis of Pax8 binding provides new insights into thyroid functions.
BMC Genomics
; 13: 147, 2012 Apr 24.
Article
in English
| MEDLINE | ID: mdl-22531031
16.
The variant rs1867277 in FOXE1 gene confers thyroid cancer susceptibility through the recruitment of USF1/USF2 transcription factors.
PLoS Genet
; 5(9): e1000637, 2009 Sep.
Article
in English
| MEDLINE | ID: mdl-19730683
17.
Correction: Díaz-Talavera et al. PrimPol: A Breakthrough among DNA Replication Enzymes and a Potential New Target for Cancer Therapy. Biomolecules 2022, 12, 248.
Biomolecules
; 12(5)2022 May 12.
Article
in English
| MEDLINE | ID: mdl-35625665
18.
PrimPol: A Breakthrough among DNA Replication Enzymes and a Potential New Target for Cancer Therapy.
Biomolecules
; 12(2)2022 02 03.
Article
in English
| MEDLINE | ID: mdl-35204749
19.
Comprehensive molecular analysis of immortalization hallmarks in thyroid cancer reveals new prognostic markers.
Clin Transl Med
; 12(8): e1001, 2022 08.
Article
in English
| MEDLINE | ID: mdl-35979662
20.
Analysis of Telomere Maintenance Related Genes Reveals NOP10 as a New Metastatic-Risk Marker in Pheochromocytoma/Paraganglioma.
Cancers (Basel)
; 13(19)2021 Sep 23.
Article
in English
| MEDLINE | ID: mdl-34638246